This HTML5 document contains 136 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n8http://linked.opendata.cz/resource/drugbank/drug/DB01241/identifier/pubchem-compound/
n16http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n12http://linked.opendata.cz/resource/drugbank/company/
n9http://linked.opendata.cz/resource/drugbank/drug/DB01241/identifier/kegg-drug/
n23http://linked.opendata.cz/resource/drugbank/dosage/
n6http://linked.opendata.cz/resource/drugbank/drug/DB01241/identifier/pubchem-substance/
n14http://linked.opendata.cz/resource/drugbank/drug/DB01241/identifier/drugbank/
n27http://www.drugs.com/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01241/identifier/iuphar/
n11http://linked.opendata.cz/resource/drugbank/drug/DB01241/identifier/guide-to-pharmacology/
n22http://bio2rdf.org/drugbank:
n10http://linked.opendata.cz/resource/drugbank/drug/DB01241/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n28http://www.rxlist.com/cgi/generic/
n30http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
n18http://linked.opendata.cz/resource/drugbank/drug/DB01241/identifier/chemspider/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n20http://linked.opendata.cz/resource/drugbank/medicinal-product/
n17http://linked.opendata.cz/resource/drugbank/drug/DB01241/identifier/chebi/
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n25http://www.pdrhealth.com/drug_info/rxdrugprofiles/drugs/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/resource/drugbank/drug/DB01241/identifier/wikipedia/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01241/identifier/pharmgkb/
n26http://linked.opendata.cz/resource/atc/
n15http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01241
rdf:type
n3:Drug
n3:description
A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol. These decreases occur primarily in the VLDL fraction and less frequently in the LDL fraction. Gemfibrozil increases HDL subfractions HDL2 and HDL3 as well as apolipoproteins A-I and A-II. Its mechanism of action has not been definitely established. [PubChem]
n3:dosage
n23:271B5DBA-363D-11E5-9242-09173F13E4C5 n23:271B5DBB-363D-11E5-9242-09173F13E4C5 n23:271B5DB9-363D-11E5-9242-09173F13E4C5
n3:group
approved
n3:halfLife
1.5 hours
n3:indication
For treatment of adult patients with very high elevations of serum triglyceride levels (types IV and V hyperlipidemia) who are at risk of developing pancreatitis (inflammation of the pancreas) and who do not respond adequately to a strict diet.
owl:sameAs
n22:DB01241 n30:DB01241
dcterms:title
Gemfibrozil
adms:identifier
n6:46508264 n7:PA449750 n8:3463 n9:D00334 n10:0115-9911-13 n11:3439 n13:3439 n14:DB01241 n17:5296 n18:3345 n19:Gemfibrozil
n3:mechanismOfAction
Gemfibrozil increases the activity of extrahepatic lipoprotein lipase (LL), thereby increasing lipoprotein triglyceride lipolysis. It does so by activating Peroxisome proliferator-activated receptor-alpha (PPARĪ±) 'transcription factor ligand', a receptor that is involved in metabolism of carbohydrates and fats, as well as adipose tissue differentiation. This increase in the synthesis of lipoprotein lipase thereby increases the clearance of triglycerides. Chylomicrons are degraded, VLDLs are converted to LDLs, and LDLs are converted to HDL. This is accompanied by a slight increase in secretion of lipids into the bile and ultimately the intestine. Gemfibrozil also inhibits the synthesis and increases the clearance of apolipoprotein B, a carrier molecule for VLDL.
n3:packager
n12:271B5D84-363D-11E5-9242-09173F13E4C5 n12:271B5D85-363D-11E5-9242-09173F13E4C5 n12:271B5D88-363D-11E5-9242-09173F13E4C5 n12:271B5D89-363D-11E5-9242-09173F13E4C5 n12:271B5DA5-363D-11E5-9242-09173F13E4C5 n12:271B5D86-363D-11E5-9242-09173F13E4C5 n12:271B5DA6-363D-11E5-9242-09173F13E4C5 n12:271B5D87-363D-11E5-9242-09173F13E4C5 n12:271B5DA3-363D-11E5-9242-09173F13E4C5 n12:271B5DA4-363D-11E5-9242-09173F13E4C5 n12:271B5DA9-363D-11E5-9242-09173F13E4C5 n12:271B5DAA-363D-11E5-9242-09173F13E4C5 n12:271B5DA7-363D-11E5-9242-09173F13E4C5 n12:271B5DA8-363D-11E5-9242-09173F13E4C5 n12:271B5D96-363D-11E5-9242-09173F13E4C5 n12:271B5D99-363D-11E5-9242-09173F13E4C5 n12:271B5D9A-363D-11E5-9242-09173F13E4C5 n12:271B5D97-363D-11E5-9242-09173F13E4C5 n12:271B5D98-363D-11E5-9242-09173F13E4C5 n12:271B5D9D-363D-11E5-9242-09173F13E4C5 n12:271B5D9E-363D-11E5-9242-09173F13E4C5 n12:271B5D9B-363D-11E5-9242-09173F13E4C5 n12:271B5D9C-363D-11E5-9242-09173F13E4C5 n12:271B5DA1-363D-11E5-9242-09173F13E4C5 n12:271B5DA2-363D-11E5-9242-09173F13E4C5 n12:271B5D9F-363D-11E5-9242-09173F13E4C5 n12:271B5DA0-363D-11E5-9242-09173F13E4C5 n12:271B5D7C-363D-11E5-9242-09173F13E4C5 n12:271B5D7D-363D-11E5-9242-09173F13E4C5 n12:271B5D7B-363D-11E5-9242-09173F13E4C5 n12:271B5D80-363D-11E5-9242-09173F13E4C5 n12:271B5D81-363D-11E5-9242-09173F13E4C5 n12:271B5D7E-363D-11E5-9242-09173F13E4C5 n12:271B5D7F-363D-11E5-9242-09173F13E4C5 n12:271B5D82-363D-11E5-9242-09173F13E4C5 n12:271B5D83-363D-11E5-9242-09173F13E4C5 n12:271B5D8C-363D-11E5-9242-09173F13E4C5 n12:271B5D8D-363D-11E5-9242-09173F13E4C5 n12:271B5D8A-363D-11E5-9242-09173F13E4C5 n12:271B5D8B-363D-11E5-9242-09173F13E4C5 n12:271B5D90-363D-11E5-9242-09173F13E4C5 n12:271B5D91-363D-11E5-9242-09173F13E4C5 n12:271B5D8E-363D-11E5-9242-09173F13E4C5 n12:271B5D8F-363D-11E5-9242-09173F13E4C5 n12:271B5D94-363D-11E5-9242-09173F13E4C5 n12:271B5D95-363D-11E5-9242-09173F13E4C5 n12:271B5D92-363D-11E5-9242-09173F13E4C5 n12:271B5D93-363D-11E5-9242-09173F13E4C5
n3:routeOfElimination
Approximately seventy percent of the administered human dose is excreted in the urine, mostly as the glucuronide conjugate, with less than 2% excreted as unchanged gemfibrozil.
n3:synonym
2,2-Dimethyl-5-(2,5-dimethylphenoxy)valeriansaeure Gemfibrozil Lopid 2,2-Dimethyl-5-(2,5-xylyloxy)valeric acid 2,2-Dimethyl-5-(2,5-xylyloxy)valeriansaeure Gemfibrozilo Gemfibrozilum
n3:toxicity
Oral, mouse: LD<sub>50</sub> = 3162 mg/kg. Symptoms of overdose include abdominal cramps, diarrhea, joint and muscle pain, nausea, and vomiting.
n15:hasAHFSCode
n16:24-06-06
n3:foodInteraction
Take 30 minutes before meals.
n3:proteinBinding
95%
n3:synthesisReference
Gianfranco Piccoli, Antonio Tarquini, Giovanni Frare, "Process for the preparation of gemfibrozil." U.S. Patent US5654476, issued May, 1980.
foaf:page
n25:lop1234.shtml n27:gemfibrozil.html n28:gemfib.htm
n3:IUPAC-Name
n4:271B5DC0-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B5DC6-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B5DC5-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B5DC2-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B5DC3-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B5DC4-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B5DBE-363D-11E5-9242-09173F13E4C5 n4:271B5DD6-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B5DBC-363D-11E5-9242-09173F13E4C5 n4:271B5DBF-363D-11E5-9242-09173F13E4C5 n4:271B5DD9-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B5DBD-363D-11E5-9242-09173F13E4C5
n15:hasATCCode
n26:C10AB04
n3:H-Bond-Acceptor-Count
n4:271B5DCC-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B5DCD-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B5DC7-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B5DC8-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B5DCA-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B5DC9-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B5DCB-363D-11E5-9242-09173F13E4C5
n3:absorption
Well absorbed from gastrointestinal tract (within 1-2 hours).
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
25812-30-0
n3:category
n3:containedIn
n20:271B5DB7-363D-11E5-9242-09173F13E4C5 n20:271B5DB8-363D-11E5-9242-09173F13E4C5 n20:271B5DB5-363D-11E5-9242-09173F13E4C5 n20:271B5DB6-363D-11E5-9242-09173F13E4C5 n20:271B5DAB-363D-11E5-9242-09173F13E4C5 n20:271B5DAC-363D-11E5-9242-09173F13E4C5 n20:271B5DAF-363D-11E5-9242-09173F13E4C5 n20:271B5DB0-363D-11E5-9242-09173F13E4C5 n20:271B5DAD-363D-11E5-9242-09173F13E4C5 n20:271B5DAE-363D-11E5-9242-09173F13E4C5 n20:271B5DB3-363D-11E5-9242-09173F13E4C5 n20:271B5DB4-363D-11E5-9242-09173F13E4C5 n20:271B5DB1-363D-11E5-9242-09173F13E4C5 n20:271B5DB2-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B5DD2-363D-11E5-9242-09173F13E4C5
n3:Boiling-Point
n4:271B5DD8-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B5DD4-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B5DD5-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B5DD7-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B5DD1-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B5DD0-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B5DD3-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B5DC1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B5DCE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B5DCF-363D-11E5-9242-09173F13E4C5